第一三共(DSNKY.US)重磅ADC新药“德曲妥珠单抗”胃癌适应症拟纳入优先审评

智通财经2025-06-11

智通财经APP获悉，6月10日，中国国家药监局药品审评中心（CDE）官网公示，第一三共（DSNKY.US）申报的注射用德曲妥珠单抗（T-DXd, DS-8201a）拟纳入优先审评，拟定适应症为：单药适用于治疗既往接受过一种治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者。德曲妥珠单抗是一款采用独有技术设计的靶向HER2的DXd抗体偶联药物（ADC），该药物由第一三共研制，并由第一...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2542373203?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-06-11 11:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542373203","market":"hk","top_or_hot":-1,"title":"第一三共(DSNKY.US)重磅ADC新药“德曲妥珠单抗”胃癌适应症拟纳入优先审评","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，6月10日，中国国家药监局药品审评中心（CDE）官网公示，第一三共（DSNKY.US）申报的注射用德曲妥珠单抗（T-DXd, DS-8201a）拟纳入优先审评，拟定适应症为：单药适用于治疗既往接受过一种治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者。德曲妥珠单抗是一款采用独有技术设计的靶向HER2的DXd抗体偶联药物（ADC），该药物由第一三共研制，并由第一...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1303797.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>第一三共(DSNKY.US)重磅ADC新药“德曲妥珠单抗”胃癌适应症拟纳入优先审评</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n第一三共(DSNKY.US)重磅ADC新药“德曲妥珠单抗”胃癌适应症拟纳入优先审评\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-06-11 11:14 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1303797.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，6月10日，中国国家药监局药品审评中心（CDE）官网公示，第一三共（DSNKY.US）申报的注射用德曲妥珠单抗（T-DXd, DS-8201a）拟纳入优先审评，拟定适应症为：单药适用于治疗既往接受过一种治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者。德曲妥珠单抗是一款采用独有技术设计的靶向HER2的DXd抗体偶联药物（ADC），该药物由第一三共研制，并由第一...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1303797.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4080","symbol_name":"零售业房地产投资信托","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1303797.html","article_id":"2542373203","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542373203","pubTimestamp":1749611666,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"基于DESTINY-Gastric01 、DESTINY-Gastric02等多项2期研究结果，德曲妥珠单抗作为HER2阳性转移性胃癌的二线和三线治疗策略已得到证实。因此，德曲妥珠单抗在多个国家或地区获批用于治疗既往接受过曲妥珠单抗治疗的HER2阳性转移性胃癌或胃食管结合部腺癌。根据第一三共公开资料介绍，DESTINY-Gastric04是德曲妥珠单抗治疗HER2阳性晚期胃癌的首个3期研究。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4080":"零售业房地产投资信托","ADC":"艾格里房产","BK4007":"制药","DSNKY":"Daiichi Sankyo Co., Ltd.","BK4231":"零售房地产信托"},"translate_title":"Daiichi Sankyo (DSNKY.US) 's blockbuster ADC new drug \"Detrastuzumab\" gastric cancer indications are planned to be included in priority review","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADC":1,"DSNKY":1},"content_text":"智通财经APP获悉，6月10日，中国国家药监局药品审评中心（CDE）官网公示，第一三共（DSNKY.US）申报的注射用德曲妥珠单抗（T-DXd, DS-8201a）拟纳入优先审评，拟定适应症为：单药适用于治疗既往接受过一种治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者。德曲妥珠单抗是一款采用独有技术设计的靶向HER2的DXd抗体偶联药物（ADC），该药物由第一三共研制，并由第一三共和阿斯利康（AZN.US）共同开发和商业化。在中国，该药此前已经在中国获批4项适应症，涵盖HER2阳性晚期乳腺癌、HER2低表达（IHC 1+或IHC 2+/ISH-）晚期乳腺癌、HER2（ERBB2）激活突变非小细胞肺癌，以及既往接受过两种或两种以上治疗方案的HER2阳性晚期胃或胃食管结合部腺癌。基于DESTINY-Gastric01 、DESTINY-Gastric02等多项2期研究结果，德曲妥珠单抗作为HER2阳性转移性胃癌的二线和三线治疗策略已得到证实。因此，德曲妥珠单抗在多个国家或地区获批用于治疗既往接受过曲妥珠单抗治疗的HER2阳性转移性胃癌或胃食管结合部腺癌。根据第一三共公开资料介绍，DESTINY-Gastric04是德曲妥珠单抗治疗HER2阳性晚期胃癌的首个3期研究。该研究总体阳性结果表明，与雷莫西尤单抗+紫杉醇相比，德曲妥珠单抗为HER2阳性（IHC 3+或IHC 2+/ISH+）转移性胃或胃食管结合部（GEJ）腺癌患者带来具有显著统计学差异和临床意义的总生存期（OS）改善。今年6月，《新英格兰医学杂志》（NEJM）发表了DESTINY-Gastric04研究结果，显示在HER2阳性转移性胃癌或胃食管结合部腺癌患者中，德曲妥珠单抗作为二线治疗展现出显著生存优势，中位总生存期（OS）达14.7个月，较标准二线治疗方案延长3.3个月（14.7个月 vs. 11.4个月），死亡风险显著降低30%。研究人员认为，这项研究证实，在HER2阳性转移性胃癌或胃食管结合部腺癌的二线治疗中，较现行标准二线治疗方案，德曲妥珠单抗能显著延长患者生存时间，且安全性可控。尽管需要关注间质性肺病风险，但该不良事件风险均为低级别。这些结果为这部分胃癌患者临床治疗提供了有力的证据，有望带来新治疗策略。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2542373203","isCrawlerRequest":true}